Tamoxifen therapy in postmenopausal advanced breast cancer: Efficacy at the primary tumor site in 46 evaluable patients

A. Veronesi, S. Frustaci, U. Tirelli, E. Galligioni, M. G. Trovò, D. Crivellari, M. D. Magri, S. Tumolo, E. Grigoletto

Research output: Contribution to journalArticle

Abstract

Forty-six evaluable postmenopausal patients with locally advanced, inoperable T 3-T 4 breast carcinoma were treated with tamoxifen 10-20 mg twice daily for at least 6 weeks. Eight patients (17%) had an objective response at the primary tumor site after 6 weeks of treatment. Improvement of response with a further single tamoxifen therapy was observed in 7 patients, resulting in an overall objective response in 14 of 46 (30%). Median duration of response was 8 months (range 2-24). No response was obtained in the 5 patients with inflammatory signs. Toxicity of treatment was minimal. Median survival was 10 months (responders 17.5, non-responders 9). Tamoxifen seems to be a safe and effective treatment for locally advanced breast cancer without inflammatory signs in postmenopausal women.

Original languageEnglish
Pages (from-to)235-238
Number of pages4
JournalTumori
Volume67
Issue number3
Publication statusPublished - 1981

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research

Cite this

Veronesi, A., Frustaci, S., Tirelli, U., Galligioni, E., Trovò, M. G., Crivellari, D., Magri, M. D., Tumolo, S., & Grigoletto, E. (1981). Tamoxifen therapy in postmenopausal advanced breast cancer: Efficacy at the primary tumor site in 46 evaluable patients. Tumori, 67(3), 235-238.